) estimates are maintained. Jefferies said that updated label removes a specific Hb target range (10-12 g/dL) and guides to individualize ESA therapy to reduce the need for red blood cell transfusions. Also, the label implies Hb target dose of 10-11 g/dL, in our view. “We estimate U.S. ESA sales in dialysis (Epogen, Aranesp) of ~$2.54B and Aranesp U.S. sales in predialysis of ~$250M. Combined, U.S. sales of Epogen and Aranesp account for ~18% of AMGN's total revenue in 2011 (decreasing to ~14% in 2015) by our estimates.” Amgen closed on Friday at $57.04.